Ocata Therapeutics Inc fka OCAT

[rocky301]

Ruff,

Once again, it takes a long winded post to detail..:)
For the sake of having a discussion on this topic let's look at it from this perspective. SMD trial is cleared by FDA and will start first. AMD needs approval and will follow SMD trial at some point.
Mytogen Phase 2 could launch in first half of 2011 which is more invasive and many more patients and has been said to cost $15MM for Phase 2. Caldwell has stated that "at least partial funding coming from “non dilutive” sources" Ok, it is therefore possible that all 3 could be ongoing by mid year 2011.

I have no clue what the Phase I/II multicenter studies will cost for either SMD or AMD. What I do know is this, if we thought we were burning through dollars before well the time is here when dollars will really roll. And this quote from todays PR, " and of course plan to scale up our operations"

The last 10Q reported the fiancing we have available(see below)

(from 10Q)
We plan to fund our operations for the next twelve months primarily from the following financings:

· During 2010, we received cash proceeds of $2,650,000 in convertible promissory note financings with JMJ Financial. As of September 30, 2010, $3,520,000 remains available to us.
· During 2010, we received $1,685,000 from the 2009 convertible debenture.
· During 2010, we received $830,165 from the issuance of our Series A-1 convertible preferred stock credit facility. The facility allows for a maximum placement of $5,000,000.
· During 2010, we received $1,985,000 from the issuance of Series B preferred stock. The agreement allows for a maximum placement of $10,000,000.
· We continue to repay our debt financings in shares of common stock, enabling us to use our cash resources to fund our operations.

As of Sept.30 that shows approx. $15.7MM available to ACT, when we call in available financing we issue shares to the note holders.
I am seeing a discrepancy from the credit lines above and what was written to poster "interstates" inquiries.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=56606130
Whomever responded stated $10MM in credit lines? So I am not 100% sure what the correct number is. It is very possible they called in more money after the Sept.30 filing..
With that said, it is very important to remember that if the pps moves and sustains levels higher than 10 cents(sustained at .20 or higher,imo) it will have debtholders wanting to exercise their 10 cent warrants. Approx. 200MM warrants at 10 cents exercised would translate into $20MM dollars for ACT coffers. If all that were to happen we would be looking at having a total of $30-$35MM availavle for all 3 trials. How far does that go? Not nearly far enough but a good start until we can partner up or secure more financing and hopefully it will be under better terms than what we have had in the past. Money will be an issue in the forseeable future, no doubt.